Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apthera Inc.

This article was originally published in Start Up

Executive Summary

Apthera was formed two years ago to further develop NeuVax, an investigational therapeutic cancer vaccine. NeuVax, which combines the T-cell peptide E75 with GM-CSF, is poised to enter Phase III testing in early-stage breast cancer patients to prevent recurrence of the disease and is also in early trials in prostate cancer,

You may also be interested in...



RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product

Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.

RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product

Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.

Amping Up Dendritic Cells

Researchers are looking for ways to better stimulate dendritic cells (DCs, the antigen presenting cells that initiate and control many aspects of the immune response) in the hopes of creating potent vaccines against tumors and infectious diseases. A recent paper highlights progress on the DC targeting front using a DNA vaccine strategy, but is also a reminder that the immunotherapy field has a long way to go.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel